Home › Uveal Melanoma
Uveal Melanoma clinical trials recruiting in the U.S.
22 studies for Uveal Melanoma are recruiting participants at sites across the United States.
Cities with the most studies
- Philadelphia, PA7 studies
- Nashville, TN6 studies
- Los Angeles, CA6 studies
- Boston, MA5 studies
- Denver, CO5 studies
- Scottsdale, AZ5 studies
- Houston, TX5 studies
- New York City, NY5 studies
- Columbus, OH5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Mountain View, CA4 studies
- Pittsburgh, PA4 studies
- Aurora, CO4 studies
- Durham, NC3 studies
- Cleveland, OH3 studies
- Madison, WI3 studies
- Chicago, IL3 studies
By state
- Arizona5 studies
- California7 studies
- Colorado7 studies
- Florida8 studies
- Illinois3 studies
- Massachusetts5 studies
- Michigan3 studies
- New York7 studies
- North Carolina4 studies
- Ohio8 studies
- Pennsylvania8 studies
- Tennessee6 studies
- Texas5 studies
- Wisconsin3 studies
Recently updated studies
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07804186A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT05607095Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06070012A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 19, 2026 · NCT07636785Tebentafusp-tebn With LDT in Metastatic UM
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06626516Adjuvant Tebentafusp in High Risk Ocular Melanoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 30, 2026 · NCT06246149Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 26, 2026 · NCT06961357Adjuvant Quisinostat in High-Risk Uveal Melanoma
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 18, 2026 · NCT06932757A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 15, 2026 · NCT06940739Neoadjuvant Tebentafusp for Uveal Melanoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 12, 2026 · NCT06414590Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
All ages · All sexes · Updated Apr 2, 2026 · NCT06581406Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07276386Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 17, 2026 · NCT04119024Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Recruiting
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT07364474Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Mar 9, 2026 · NCT04792463Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT06627244Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 4, 2025 · NCT06121180Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 28, 2025 · NCT07136181A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.